2 Preventive Care and Screening Adherence Among Women Surviving Breast Cancer

News
Article
Miami Breast Cancer Conference® Abstracts Supplement42nd Annual Miami Breast Cancer Conference® - Abstracts
Volume 39
Issue 4
Pages: 60

2 Preventive Care and Screening Adherence Among Women Surviving Breast Cancer

2 Preventive Care and Screening Adherence Among Women Surviving Breast Cancer

Background/Significance

Preventive care and screening adherence are essential to long-term follow-up for breast cancer survivors, enabling detection of recurrence and guiding overall health maintenance. Routine physical exams, mammograms, and Pap smears are recommended. Barriers to adherence over time can be addressed by community-based organizations by providing information and supportive services, including navigation to screening. We studied adherence to preventive care and screening among breast cancer survivors who engaged a national cancer control community-based organization–examining how sociodemographics, cancer care factors, and quality of life were associated with adherence.

Materials and Methods

A secondary data analysis was conducted among breast cancer survivors (n = 777) who contacted the community-based organization for resources, including no-cost patient navigation. Patient-reported outcomes were assessed after 30 days, along with survivorship care plan (SCP) quality and quality of life. An index score was created based upon women’s self-reported adherence to receiving routine physical exams, mammograms, and Pap smears at recommended intervals.

Results

Among survivors, 37% were age ≤ 46 years, 19% were non-White, 63% were in a partnered relationship, 23% rated their quality of life (general health) as fair/poor, and 47% carried a pathogenic variant in BRCA. Medical providers caring for these survivors were primary care physicians (53.6%) and oncology specialists (46.4%). For index scores, 66% were adherent to all 3 recommendations for follow-up, 29% to 2 recommendations, and 6% to ≤ 1 recommendation. The most adhered to recommendation was a physical exam (97%), and the least was a Pap smear (73%); 88% of survivors reported mammograms biannually. At the bivariate level, survivors who were younger (t, df = 4.59, 711, P <.001), non-White (t, df = –3.27, 267, P <.001), in a partnered relationship (t, df = 1.76, 54, P <.05), and with better quality of life (r = –.09, P <.01) were more adherent. A trend was observed for SCP quality; survivors who received written summaries (56%), including follow-up instructions (64%), and in written form (45%), were more likely to adhere (r = .05, P <.10). In a multivariable regression model adjusting for partnership status and SCP quality, younger survivors (B = 1.13, P <.001), who were non-White (B = 1.0, P <.01), and with better quality of life (B = .09, P <.05) were more adherent.

Conclusion

Survivors can be navigated to guideline-based prevention and screening with community-based organization-led support. Tailored SCPs are essential to reinforce life-saving health behaviors and improve follow-up adherence.

Articles in this issue

2 Preventive Care and Screening Adherence Among Women Surviving Breast Cancer
2 Preventive Care and Screening Adherence Among Women Surviving Breast Cancer
3 Intraoperative Radiotherapy: Alive and Well in the Bronx
3 Intraoperative Radiotherapy: Alive and Well in the Bronx
4 Evaluating AI-Driven Responses in Breast Reconstruction: A Comparative Study of Response Formats
4 Evaluating AI-Driven Responses in Breast Reconstruction: A Comparative Study of Response Formats
5 Correlation Between Visual Impairment and Breast Cancer: A Cross-Sectional Study Based on the National Health Interview Surveys
5 Correlation Between Visual Impairment and Breast Cancer: A Cross-Sectional Study Based on the National Health Interview Surveys
6 Peer Support Programming Among Women At-Risk for Surviving Breast Cancer: Facilitators and Barriers to Community-Based Patient Navigation and the Role of Quality of Life
6 Peer Support Programming Among Women At-Risk for Surviving Breast Cancer: Facilitators and Barriers to Community-Based Patient Navigation and the Role of Quality of Life
7 Metaplastic Breast Cancer: A Retrospective Chart Review of Clinical Features
7 Metaplastic Breast Cancer: A Retrospective Chart Review of Clinical Features
8 A Case Series Exploring Characteristics and Outcomes of Metachronous Primary Breast and Lung Cancer in a Diverse Cohort
8 A Case Series Exploring Characteristics and Outcomes of Metachronous Primary Breast and Lung Cancer in a Diverse Cohort
9 Body Mass Index, Cancer Risk Behaviors, and Readiness for Dietary Change Among Women Surviving With Breast Cancer
9 Body Mass Index, Cancer Risk Behaviors, and Readiness for Dietary Change Among Women Surviving With Breast Cancer
10 AI as a Bridge: Can ChatGPT Help Patients Understand Their Breast Radiology Reports?
10 AI as a Bridge: Can ChatGPT Help Patients Understand Their Breast Radiology Reports?
12 Gut Microbiome Composition and Pathological Complete Response After Chemotherapy in Breast Cancer: Insights From a Pilot Study
12 Gut Microbiome Composition and Pathological Complete Response After Chemotherapy in Breast Cancer: Insights From a Pilot Study
13 Preliminary Analysis of Change During Treatment of Financial Toxicity and Quality of Life in Breast Cancer Patients
13 Preliminary Analysis of Change During Treatment of Financial Toxicity and Quality of Life in Breast Cancer Patients
15 Utilizing Circulating Tumor Cells to Guide HER2-Directed Therapy in IHC/FISH-Negative HER2+ Metastatic Breast Cancer
15 Utilizing Circulating Tumor Cells to Guide HER2-Directed Therapy in IHC/FISH-Negative HER2+ Metastatic Breast Cancer
16 A Miami Hospital’s Infrastructure to Help Decrease Late-Stage Breast Cancer Diagnosis and Improve Health Equity
16 A Miami Hospital’s Infrastructure to Help Decrease Late-Stage Breast Cancer Diagnosis and Improve Health Equity
17 Salmonella and the Breast: A Literature Review of Salmonella-Induced Breast Abscesses
17 Salmonella and the Breast: A Literature Review of Salmonella-Induced Breast Abscesses
18 Tolerability of First-Line Treatment With Ribociclib for Metastatic Breast Cancer Using 2 Large US Data Sources
18 Tolerability of First-Line Treatment With Ribociclib for Metastatic Breast Cancer Using 2 Large US Data Sources

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Patients with node-negative disease who are older and have comorbidities may not be suitable to receive CDK4/6 inhibitors.
An observed carryover effect with CDK4/6 inhibitors may reduce the risk of recurrence years after a patient stops treatment.
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.
Following progression on a CDK4/6 inhibitor, ascertaining the endocrine sensitivity of HR-positive/HER2-negative disease may inform sequential treatment.
T-DXd improved progression-free survival over standard chemotherapy among patients with HR-positive/triple-negative breast cancer in DESTINY-Breast04.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.